Call Us: +233-0266-839961 | 0503 030999

Dr. Stanley MoffatDr. Stanley Saamoah Moffatt (PhD; FAAN)

(Vice President, Academic)


Contact:

Phone: 0302324541 
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Office Hours:

Primary Department: School of Informatics & Engineering

 

 

Education/Work Experience:

  • Assistant Professor, NOVA Southeastern University, FL, USA
    • (Biomedical Engineering; Bio-nanotechnology),  2006-2008
  • Research Fellow, University of Texas, TX, USA
    • (Bioengineering; Bio-nanotechnology),  2002-2006
  • Post-doctoral Fellow, Purdue University, IN, USA
    • (Bioengineering; Bio-nanotechnology),  1998-2002
  • Post-doctoral Fellow, Tohoku University School of Medicine, Japan
    • (Molecular Pathology; Genetic Engineering),  1996-1998
  • PhD, Tohoku University School of Medicine, Japan
    • (Molecular Pathology; Bioengineering),  1991-1996
  • BSc, University of Ghana, Legon,  1988

 

Brief Biography:

Dr. Moffatt is currently the Vice President for Institutional Advancement. Before joining Regent-Ghana in 2009, Dr. Moffatt was a senior researcher at the University of Texas and Assistant Professor at Florida Southeastern University in the United States, where he applied the principles of nanotechnology - engineering at a molecular level - to the design of a new class of nanotechnology-based therapeutics. His research interests include the development and application of shaped polymeric and fabricated nanomaterials for various biomaterials applications, including drug delivery and targeting, research of which incorporates several leading technology platforms including transcriptomics, proteomics, and bioinformatics.

Dr Moffatt is an astute and prolific researcher whose current research in Biomedical and Genetic Engineering hinges on the formulation and development of active macromolecular biological entities, particularly, nano-encapsulated polymeric particles for tumor delivery. Dr. Moffatt led a team in the United States in designing and developing a polymer-based therapeutics model involving a novel peptide linkage system for the tumor-specific molecule, CD13, which was published in several peer-reviewed international nanotechnology journals. Dr. Moffatt has made numerous presentations at various international meetings in the UK, USA and Asia in this interesting and dynamic area of research. As his contribution to the area of bio-nanotechnology in developing countries, Dr. Moffatt was recently appointed the Africa Coordinator for USEACANI (US-Europe-Asia Pacific- Caribbean Nanotechnology Initiative). He is a devoted christian and enjoys reading scientific literature.

 

Courses Teaching/Taught at Regent University:

  • Human Biology
  • Medical Imaging
  • Biomedical Instrumentation
  • Technical Report Writing

 

Editorial/Review Duties:

  • Bioinformatics, USA
  • Anticancer Therapy, USA
  • Journal of Nanotechnology Progress International (JONPI), USA
  • Journal of Nanomedicine and Nanotechnology, USA
  • Journal of Biomedical Materials Research, USA
  • African Journal of Biomedical Science, Kenya
  • Journal of Applied Biotechnology, India

 

Grants:

  • Co-applicant, NIH Grant for prostate cancer immunotherapy, at University of Texas MD Anderson Cancer Center,  2003- 2006, TX, USA
  • Susan Komen’s Research Grant at University of Texas MD Anderson Cancer Center, 2002 – 2004, TX, USA
  • Susan Komen’s Post-doctoral Fellowship at University of Texas MD Anderson Cancer Center, 2002 – 2004, TX, USA
  • Keck Post –doctoral Fellowship at Purdue University, 2000 – 2002, IN, USA
  • Research Assistantship at Purdue University, 1998 – 2000, IN,  USA.
  • Core Research for Evolutional Science and Technology (CREST) Research Fellowship at Tohoku University Medical School, 1996 – 1998, Japan.

 

Conferences and Awards:

  • Travel Award : 8th European Congress on Chemical Engineering (1st European Conference of Applied Biotechnology), 2011, Berlin, Germany, 25-29 September 2011,
  • Travel Award: 1st International Workshop on Nanomedicine for Infectious Diseases of Poverty 2011, Magaliesburg, South Africa, 27-31 March, 2011.
  • Travel Award: 1st  International Conference on Nanotechnology,“Nanotech India 2010, Cochin, India, 20-23 November, 2010.
  • Travel Award: International Workshop on Bio-Nanotechnology; United States-European-Caribbean-Nanotechnology Initiative (USEACANI) Workshop. Sao Paulo, Brazil. 12-15 October, 2009.
  • Travel Award:  The XVth Annual Congress of the European Society of Gene and Cell Therapy. Rotterdam, The Netherlands, 27-30 October 2007
  • Travel Award: American Society of Gene Therapy (ASGT) Washington DC, USA, June, 2003.
  • Travel Award: Japanese Government Grant , European Society for Gene Therapy (ESGT), Congress, Netherlands. May, 1998
  • Travel ward: Japanese Government Grant , International Congress on Virology  (ICV) , Israel, June, 1996
  • Fellowship: Japanese Government Fellowship for Core Research in Evolutional Science and Technology (CREST), Sendai,  Japan, June 1996-1998
  • Scholarship: Japanese Government  Scholarship (MONBUSHO)  for Graduate Studies. Sendai, Japan, 1991-1996
  • Fellowship: A 1-year Training in Virology and Pathology at Noguchi Memorial Institute for Medical Research. Accra, Ghana, 1990 – 1991
  • Teaching Assistantship: University of Ghana, Legon, Ghana 1988-1990

 

 

International Conferences and Presentations:

  • Invited Speaker:

8th European Congress on Chemical Engineering (1st European Conference of Applied Biotechnology), 2011,   -A Conference on how Biotechnology and Nanotechnology will be shaping our future. - Nanomedicine in Africa: Myth or Reality?. Berlin, Germany, 25-29 September 2011.

  • Invited Speaker:

1st International Workshop on Nanomedicine for Infectious Diseases of Poverty – A Conference on how strides in Nanomedicine could eradicate Diseases prevalent in Africa. - Bio-nanomedicine: The Magic Bullet for  Prostate Cancer Eradication. Magaliesburg, South Africa, 27-31 March, 2011.

  • Invited Speaker:

1st  International Conference on Nanotechnology,“Nanotech India 2010” - Peptide Delivery Mediated by a Novel Polymeric Platform. Cochin, India, 20-23 November, 2010.

  • Invited Speaker:

United States-European-Caribbean-Nanotechnology Initiative (USEACANI) Workshop. Bio-Nanotechnology in Africa. Sao Paulo, Brazil. 12-15 October, 2009.

  • Invited Speaker:

United States-European-Caribbean-Nanotechnology Initiative (USEACANI) Workshop. “An Efficient and Vesatile DNA Coupling System for Targeting Nanoparticles to Human Monocyte-Derived Dendritic Cells: Implications for DNA Vaccination”. Cairo, Egypt, 27 – 29 June, 2009.

  • Invited Speaker: 

The XVth Annual Congress of the European Society of Gene and Cell Therapy – Immunotargeting the CD13 peptide for efficient immunotherap. Rotterdam, The Netherlands, 27-30 October 2007

  • Invited speaker:

NSTI, Nanotechnology (Drug Delivery and Therapeutics) - A Novel Peptide-Gene Assembly Device  for Efficient Delivery to Mammalian Cells. Boston, MA, USA, 2-4 May, 2006

  • Invited speaker:

American Society of Gene Therapy (ASGT) - Successful  in-vivo Immuno-targeting of Prostate Specific Membrane Antigen with a Novel J591/PEI/DNA Molecular Conjugate . St. Louis, Missouri, USA, 2-5 June, 2005

  • Invited Speaker:

American Society of Gene Therapy (ASGT)  - Uptake Characteristics of NGR-Coupled Nanoparticles in Dendritic Cells. Minneapolis, MN, USA., 3-6 June, 2004.

  • Invited Speaker:

American Association for Cancer Research (AACR)  - DNA Immunization with Bovine Adenovirus. Orlando, FL, USA. 5-8 March, 2004.

  • Invited Speaker:

European Society for Gene Therapy (ESGT) Congress – Parvovirus B19 Capsid as a Vehicle for Gene Therapy. Rotterdam, Netherlands, 21 – 24 May, 1998.

  • Invited Speaker:

International Congress on Virology  (ICV) -  Human Parvovirus B19 and Sickle Cell Anaemia,  Jerusalem, Israel, 5-9 June, 1996

 

Peer Reviewed Publications:

  • Moffatt S, Wiehle S, and Cristiano R (2012). Combined Formulation of Doxorubicin-Arg-Gly-Asp ( RGD) and Modified PEGylated PLGA-encapsulated Nanocarrier improves Anti-tumor Activity Int. Jnl of Nanosci. and Nanotechnol. (submitted).
  • Moffatt S, Wiehle S and Cristiano R (2012).Diagnostic and Immuno-therapeutic Evaluation of Monoclonal Antibodies for the Extracellular Domain of Prostate-specific Membrane Antigen Int. Jnl of  Med. and Pharm. Sci. (in press).
  • Moffatt S (2012).Nanoengineering Strategies for Antibody-Nanoparticle Conjugates: Overview, Challenges and Promises.  Int. Jnl of Nanosci. and Nanotechnol., 3(1): 1-20
  • Moffatt S and Derrick Ansie (2012).Immunoreactive Evaluation of  the Extracellular Epitope of Prostate-specific Membrane Antigen: In Vitro Diagnostic and Therapeutic Potential.  Int. Jnl of Biochem. and Biotechnol., 8 (1): 1-16 .
  • Duran-Jimenez B, Dobler D, Moffatt S, Rabbani N, Streuli CH, Thornalley DR, and Gardiner NJ (2009). Advanced glycation end products in extracellular matrix proteins contribute to the failure of sensory nerve regeneration in diabetes. Diabetes., 58(12):2893-903.
  • Gardiner NJ, Moffatt S, Fernyhough P, Humphries MJ, Streuli CH, Tomlinson DR (2007).  Preconditioning injury-induced neurite outgrowth of adult rat sensory neurons on fibronectin is mediated by mobilization of Axonal alpha5 integrin. Mol Cell Neurosci. 2:249-260.   
  • Moffatt S, Wiehle S, and Cristiano R (2006). Uptake characteristics of NGR-coupled stealth PEI/pDNA nanoparticles loaded with PLGA-PEG-PLGA triblock copolymer for targeted delivery to human monocyte-derived dendritic cells Int. J. Pharm., 321:143-154.
  • Moffatt S and Cristiano RJ (2006). A PEGylated J591  mAb loaded on PLGA-PEG-PLGA tri-block copolymer for targeted delivery: in vitro pharmacokinetic and pharmacodynamic evaluation in prostate cancer cells. Int. J. Pharm., 317 (1): 10-13.
  • Moffatt S, Wiehle S and Cristiano RJ. (2006). A multifunctional PEI-based cationic polyplex for enhanced systemic p53-mediated gene therapy. Gene Ther 13 (21): 1512-1523.
  • Moffatt S, Papasakelariou C, Wiehle S, Cristiano R. (2006). Successful in vivo immuno-targeting of prostate specific membrane antigen with a novel J591/PEI/DNA molecular conjugate.Gene Therapy 13 (9):761-772.
  • Moffatt S, Wiehle S,  Cristiano RJ (2005). Tumor specific gene delivery mediated by a novel peptide/polyethyeneimine/DNA polyplex targeting aminopeptidase N (CD13). Human Gene Therapy, 16: 57-67.
  • Shen D, Moffat S, Resnick SM, Davatzikos C (2002).   Measuring Size and Shape of the Hippocampus in MR Images Using a Deformable Shape Model, NeuroImage, 15(2): 422-434.
  •  Barclay J, Patel S, Dorn G, Wootherspoon G, Moffatt S, Eunson L, Abdel’al S, Natt F, Hall J, Winter J, Bevan S, Wishart W, Fox A, Ganju P. (2002). Functional downregulation of P2X3 receptor subunit in rat sensory neurons reveals a significant role in chronic neuropathic and inflammatory pain. J Neurosci., 22(18): 8139-47.
  •  Bennett JH, Moffatt S, Horton M (2001). Cell adhesion molecules in human osteoblasts: structure and function. Histol Histopathol., 16(2):603-11. Review.
  •  Mittal SK, Aggarwal N, Sailaja G, van Olphen A, HogenEsch H, North A, Hays J,   Moffatt S (2000). Immunization with DNA,adenovirus, or both in biodegradable alginate microspheres: effect of route of inoculation on immune response. Vaccine, 19: 253-263.
  •  Moffatt S, Hays J, HogenEsch H, Mittal SK (2000).Circumvention of vector-specific  neutralizing antibody response by alternating use of  human and non-human adenoviruses: Implications in gene therapy. Virology. 272:159-167.
  •  Yaegashi N, Niinuma T, Chisaka H, Uehara S, Moffatt S, Tada K, Iwabuchi M, Matsunaga Y, Nakayama M, Yutani C,  Osamura  Y, Hirayama E, Okamura K, Sugamura K, Yajima A (1999). Parvovirus B19 infection induces apoptosis of erythroid cells in vitro and in vivo. J. Infect. 39:68-76.
  •  Yaegashi N, Niinuma T, Chisaka H, Uehara S, Okamura K, Shinkawa O, Tsunoda A, Moffatt S, Sugamura K, Yajima A (1999). Serologic study of human parvovirus B19 infection in pregnancy in Japan. J. Infect 38: 30-35.
  •  Yaegashi N,  Niinuma T,  Chisaka H,  Watanabe T,  Uehara S,  Okamura K,  Moffatt S,  Sugamura K, Yajima A (1998). The Incidence of, and factors leading to, parvovirus B19-related hydrops fetalis following maternal infection: report of 10 cases and meta-analysis. J.  Infect. 37: 28-35.
  •  Moffatt S, Yaegashi N, Tada K, Tanaka N, Sugamura K. (1998). Human Parvovirus B19 Non-Structural (NS1) Protein Induces Apoptosis in Erythroid Lineage Cells. J. Virol., 72: 3018-3028.
  •  Oda K, Asao H, Higuchi M, Moffatt S, Masataka Nakamura, Koichi Tabayashi and Kazuo Sugamura (1997). Induction of IL-1b-converting enzyme-independent apoptosis by IL-2 in Human T cell Lines. Int. Jnl. Immunol. 9: 1303-1310.
  • Moffatt S, Tanaka N, Tada K, Nose M, Nakamura M, Muraoka, O, Hirano T, Sugamura K (1996). A cytotoxic non-structural (NS1) protein of human parvovirus B19 induces activation of interleukin-6 gene expression. J. Virol., 70: 8485-8491.

 

Refereed Publications

  1. Stanley Moffatt, Walter Hiddelman, and Mahindra Donarein (2015). Nanoparticle-Mediated Targeted Therapy with a Novel Tumor Enzyme-Activated Delivery System(TEADS).  Int. Jnl of Nanosci. and Nanotechnol. 6(1): 9 - 19.
  2. Stanley Moffatt, (2015). Nanoparticle PEGylation for Cancer Therapy. MOJ Proteomics &  Bioinformatics. 2(1): 1 - 3.
  3. Stanley Moffatt, (2014). Targeted Nanotechnology: Delivering Small but Deadly Punches. MOJ Proteomics &  Bioinformatics. 1(1): 1 - 3.
  4. Stanley Moffatt, Richard Cristiano and Rose Boyle (2013). Combined Formulation of Doxorubicin-Arg-Gly-Asp ( RGD) and Modified PEGylated PLGA-encapsulated Nanocarrier improves Anti-tumor Activity.  Int. Jnl of Nanosci. and Nanotechnol. 4(1): 19 - 34.
  5. Perotti C, Karayazi O, Moffat S, and Shemanko CS (2012). The bone morphogenetic protein receptor-1A pathway is required for lactogenic differentiation of mammary epithelial cells in vitro. In Vitro Cell Devt. Biol. 48: 377 – 384.
  6. Stanley Moffatt, John Hayes, Kazuo Hitoshi, Sandra Wiehle (2012). BMP signaling is required for proper differentiation of prostate progenitor cells. In Vitro Cell Devt. Biol. 38: 237 – 243.
  7. Stanley Moffatt  (2012). Nanoengineering Strategies for Antibody-Nanoparticle Conjugates: Overview, Challenges and Promises.  Int. Jnl of Nanosci. and Nanotechnol., 3(1): 1-20.
  8. Stanley Moffatt and Derrick Ansie (2011). Immunoreactive Evaluation of  the Extracellular Epitope of Prostate-specific Membrane Antigen: In Vitro Diagnostic and Therapeutic Potential.  Int. Jnl of Biochem. and Biotechnol., 8 (1): 1-16.
  9. Stanley Moffatt (2011). Cooperative dual-activity targeted nanomedicine for specific and effective prostate cancer therapy – insights and perspectives. Int. Jnl of Nanosci. and Nanotechnol. 1(1): 11 - 15.
  10. William Cain, Stanley Moffatt, Phil Drexdel (2010). cRGD-Conjugated Polycationic nanoparticle as a Targetable Delivery System Directed to Cells Possessing αvβ3-specifc- expressing prostate cancer cells. .  Int. Jnl of Nanosci. and Nanotechnol., 1(1): 4-18.
  11. Stanley Moffatt, William Cain, Phil Drexdel, Jeff Shu (2009). Targeted therapy for prostate tumors using cRGD-entrapped polymeric nanomicelles. Int Jnl Nanomed 55(5): 42 – 51.
  12. Stanley Moffatt, William Cain, Phil Drexdel, Jeff Shu (2009). Cyclic-RGDfK peptide conjugated nanomicelles for targeted delivery of doxirobucin to integrin receptor over-expressing angiogenic tumours.  Int Jnl Nanomed 54(4): 36 – 41.
  13. Stanley Moffatt, Sandra Wiehle and Richard Cristiano (2008). Tumor regression following intravenous administration of lactoferricin-bearing RGD-coupled dendriplexes. Therapeutics., 62:22-28.
  14. Sandra Wiehle, Stanley Moffatt, and Richard Cristiano (2008). Elucidation of lactoferrin-binding epitopes through r- lactoferrin and c-RGD motifs on human prostate cancer cells. Therapeutics., 59:18-24.
  15. Stanley Moffatt and Richard Cristiano (2007). Nanoparticle-based sorting of circulating tumor cells by RGD epithelial expression during disease progression in an animal model . Int. J. Pharm., 319:10-16.
  16. Stanley Moffatt and Richard Cristiano (2007). Delivery of Therapeutics: Current Status and Its Relevance to Prostate Cancer. Therapeutics., 19:12-17.
  17. S. Moffatt, S. Wiehle and RJ Cristiano (2006). A multifunctional PEI-based cationic polyplex for enhanced systemic p53-mediated gene therapy. Gene Ther 13 (21): 1512-1523.
  18. Stanley Moffatt and Richard Cristiano (2006). Uptake characteristics of NGR-coupled stealth PEI/pDNA nanoparticles loaded with PLGA-PEG-PLGA triblock copolymer for targeted delivery to human monocyte-derived dendritic cells Int. J. Pharm., 321:143-154.
  19. Moffatt S, Papasakelariou C, Wiehle S, Cristiano R. (2006). Successful in vivo immuno-targeting of prostate specific membrane antigen with a novel J591/PEI/DNA molecular conjugate. Gene Therapy 13 (9):761-772.
  20. Stanley Moffatt and Richard Cristiano (2006). PEGylated J591 mAb loaded in PLGA-PEG-PLGA tri-block copolymer for targeted delivery: In vitro evaluation in human prostate cancer cells. Int. J. Pharm., 317:10-13.
  21. Stanley Moffatt, William Cain, Richard Cristiano (2005). A multifunctional peptide for targeted imaging and chemotherapy for nasopharyngeal and breast cancers. Hum Gene Therapy 18: 26 – 34.
  22. Stanley Moffatt, Sandra Wiehle and Richard  J. Cristiano (2005). Tumor specific gene delivery mediated by a novel peptide/polyethyeneimine/DNA polyplex targeting aminopeptidase N (CD13). Human Gene Therapy, 16: 57-67.
  23. Cullinan P, Harris J, Mills P, Moffat S, White C, Figg J, Moon A, Newman Taylor AJ. (2004). Early prescriptions of antibiotics and the risk of allergic disease in adults: a cohort study. Thorax, 59: 11 – 15.
  24. Zutavern A, von Mutius E, Harris J, Mills P, Moffatt S, White C, Cullinan P. (2004). The introduction of solids in relation to asthma and eczema. Arch Dis Child, 89: 303 – 308.
  25. Cullinan P, MacNeill SJ, Harris JM, Moffatt S, White C, Mills P, Newman Taylor AJ. (2004). Early allergen exposure, skin prick responses, and atopic wheeze at age 5 in English children: a cohort study. Thorax, 59: 855 – 861.
  26. Stanley Moffatt  (2003). Early allergen exposure: An immunological  or Genetic pre-disposition or both? Lett in Immunol. 23(8): 23 - 28
  27. Phil Drexdel and Stanley Moffatt (2002). Investigation of hydrophobically derivatized hyperbranched polyglycerol with PEGylated shell as a nanocarrier for systemic delivery of chemotherapeutics. Therapeutics 9: 20 - 25
  28. Stanley Moffatt (2002). Multilayer nanoencapsulation: A nanomedicine technology for prostate cancer research and management. Prostate 26: 36 - 43
  29. Mittal SK, Aggarwal N, Sailaja G, van Olphen A, HogenEsch H, North A, Hays J,   Moffatt S (2000). Immunization with DNA,adenovirus, or both in biodegradable alginate microspheres: effect of route of inoculation on immune response. Vaccine, 19: 253-263.
  30. Stanley Moffatt, John Hays, Harm HogenEsch, and Suresh Mittal (2000).Circumvention of vector-specific neutralizing antibody response by alternating use of  human and non-human adenoviruses: Implications in gene therapy. Virology. 272:159-167.
  31. Yaegashi N, Niinuma T, Chisaka H, Uehara S, Moffatt S, Tada K, Iwabuchi M, Matsunaga Y, Nakayama M, Yutani C,  Osamura  Y, Hirayama E, Okamura K, Sugamura K, Yajima A (1999). Parvovirus B19 infection induces apoptosis of erythroid cells in vitro and in vivo. J. Infect. 39:68-76.
  32. Yaegashi N, Niinuma T, Chisaka H, Uehara S, Okamura K, Shinkawa O, Tsunoda A, Moffatt S, Sugamura K, Yajima A (1999). Serologic study of human parvovirus B19 infection in pregnancy in Japan. J. Infect 38: 30-35.
  33. N. Yaegashi,  T. Niinuma,  H. Chisaka,  T. Watanabe,  S. Uehara,  K. Okamura,  S. Moffatt ,  Sugamura K, Yajima A (1998). The Incidence of, and factors leading to, parvovirus B19-related hydrops fetalis following maternal infection: report of 10 cases and meta-analysis. J.  Infect. 37: 28-35.
  34. Stanley Moffatt, Nobuo Yaegashi, Kohtaro Tada, Nobuo Tanaka, Kazuo Sugamura  (1998). Human Parvovirus B19 Non-Structural (NS1) Protein Induces Apoptosis in Erythroid Lineage Cells. J. Virol., 72: 3018-3028.
  35. Oda K, Asao H, Higuchi M, Moffatt S, Masataka Nakamura, Koichi Tabayashi and Kazuo Sugamura (1997). Induction of IL-1b-converting enzyme-independent apoptosis by IL-2 in Human T cell Lines. Int. Jnl. Immunol. 9: 1303-1310.
  36. Moffatt S, Tanaka N, Tada K, Nose M, Nakamura M, Muraoka, O, Hirano T, Sugamura K (1996). A cytotoxic non-structural (NS1) protein of human parvovirus B19 induces activation of interleukin-6 gene expression. J. Virol., 70: 8485-8491.

 

Research/Scholarly Interests:

  • Biomedical Engineering
  • Genetic Engineering
  • Medical Imaging
  • Nanotechnology; Nanomedicine
  • Targeted Gene Therapy

 

Memberships of Professional Bodies:

  1. American Association of Nanotechnology (USA)
  2. American Society for Gene Therapy (USA)
  3. American Association for Clinical Research (USA)
  4. Ghana Association of Biomedical Scientists (Ghana)

 

Recent Conferences, Presentations etc:

  • Invited Speaker: Inauguration of FONAI by President Obama, Washington DC, USA, August, 2010. (http://fonai.org/uploads/speakers_April.pdf)
  • Invited Speaker: USEACANI , India, August, 2009.
  • Invited speaker: Frontiering Bio-nanotechnology , Imperial College of Science, Technology and Medicine, London, UK, May 2007
  • Invited speaker: NSTI, Nanotechnology (Drug Delivery and Therapeutics) Boston, MA, USA, May, 2006
  • Invited speaker: American Society of Gene Therapy (ASGT) St. Louis, Missouri, USA, June, 2005
  • Travel award: American Society of Gene Therapy (ASGT) Minneapolis, MN, USA, June, 2004.
  • Invited Speaker: American Association for Cancer Research (AACR), Orlando, FL, USA. March, 2004.
  • Travel Award: American Society of Gene Therapy (ASGT) Washington DC, USA, June, 2003
  • Travel Award: Japanese Government Travel Grant, European Society for Gene Therapy (ESGT) Amsterdam, May, 1998
  • Travel Award: Japanese Government Travel Grant, International Congress on Virology (ICV) Israel, June, 1996
  • Fellowship: Japanese Government Fellowship for Core Research in Evolutional Science and Technology (CREST) Japan, June 1996-1998
  • Scholarship: Japanese Government (MONBUSHO) Scholarship for Graduate Studies, Japan, 1991-1996

 

Conference Papers 

  1. Stanley Saamoah-Moffatt, Sandra Wiehleand Richard J. Cristiana (2004). Enhanced Gene Delivery by a Novel Tumor-Specific Vector Containing Peptide and Nucleic Acid Based Nuclear Translocation Signals. Molecular Therapy, 9: S137–S138; doi: 10.1016/j.ymthe.2004.06.288
  2. Saamoah-Moffatt Stanley, Wiehle Sandra and Cristiano Richard J.(2005). A Novel Multi-Component Molecular Conjugate Vector for Highly Efficient p53-Mediated Tumor-Specific Gene Therapy. Molecular Therapy; Jun 2005, Vol. 11, p302-3-303. Accession No. 18293785
  3. Stanley Moffatt, Richard Cristiano and Rose Boyle (2013). Combined formulation of Doxorubicin-Arg-Gly-Asp (RGD) and modified PEGylated PLGA-encapsulated nanocarrier improves anti-tumor activity. Proceedings - 2012 IEEE International Conference on Bioinformatics and Biomedicine Workshops, BIBMW 2012.

 

Awards, Appointments, Promotions, Prizes & Fellowships: